Courtesy of Antisense Therapeutics Ltd. Antisense strategies use polymeric nucleic acids or nucleic acid analogs to bind to and silence specific messenger RNAs. The silencing can be caused either by ...
Biogen Inc. BIIB on Tuesday entered into an agreement with Alloy Therapeutics Inc. to accelerate the development of antisense ...
The function of non-coding RNA in the cell has long been a mystery to researchers. Unlike coding RNA, non-coding RNA does not produce proteins – yet it exists in large quantities. A research team from ...
Thank you for your article on antisense 1 and for letting us know that the subject is very much alive. Although antisense is an "RNA therapeutic" in that the target is mRNA, actually in almost all ...
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/q3z4pf/pharmasphere) has announced the addition of the "PharmaSphere ...
Alloy Therapeutics inks multi-target collaboration and license pact with Biogen for use of Alloy’s AntiClastic ASO platform: Boston, Massachusetts Wednesday, April 8, 2026, 16:0 ...
HOUSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a ...
HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a ...
As people age, it becomes harder to know who is on track for healthy years ahead and who may be at higher risk for serious decline. A new study suggests that part of the answer may already be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results